Single-cell-based identification of drug synergy with immunotherapy via tumor microenvironment remodeling

Read full text Summarise with VIRAT
Authors: Ziruoyu Wang, Junchi Hu, Kailu Liu, Jie Xu, Jiao Li, Yihang Liu, Qinfeng Ma, Yu Dong, Yunmei Zhu, Kai Zhang, Dexin Wang, Xiaobo Wang
+7 more Shuai Wang, Jianbo Pan, Shuai Jiang, Jiaxue Wu, Wei I. Jiang, Ling Zhang, Yongjun Dang
Cited by: 0
References: 48

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Identifying effective therapeutic drugs in the intricate tumor microenvironment (TME) is challenging, further complicated by the lack of a systematic framework for analyzing TME perturbations in response to therapeutic interventions. METHODS: To address this, we established the single-cell RNA sequencing repository of immunomodulatory drugs resource and used the L1000 platform for unbiased screening of 739 immune-modulating compounds across various cancers. RESULTS: Drug responses in mouse model revealed 12 distinct meta-programs associated with TME remodeling, enriched in biological processes such as antigen presentation, tissue repair, and salt stress response. Notably, myeloid-derived suppressor cells were markedly reduced in responsive TMEs compared with other cell types, underscoring their key immunosuppressive role. We developed an MP scoring algorithm to quantify TME responsiveness, which successfully identified allopurinol-a gout medication-as a potent enhancer of anti-programmed cell death protein-1 therapy. This combination led to significant tumor-free outcomes (4/6) in vivo. CONCLUSIONS: This work provides a robust framework for assessing TME remodeling that uncovers genes and compounds that significantly modulate immunotherapeutic efficacy.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Single-cell and spatial transcriptomics Immune cells in cancer

Publication details

Journal / source
Journal for ImmunoTherapy of Cancer
Volume
14
Issue
3
Pages
e014132–e014132
Publication date
1 March 2026
Language
EN